Investment Q&A

Q: I have listed the small/med/cap companies I have on my watch list and am seeking your advise as to which three companies you would recommend my investing in from this list. (or some other that I have not listed) Many of these companies you have recommended on BNN. I look forward to your answer.

Q: Prometic announced a small ($9.5 million) purchase order from an existing client last Friday, and they seem primed for several growth opportunities/catalysts in 2017. Yet the share price keeps dropping.
Would you be on board with an initial purchase at this time? Or wait for more good news?
Thank you.

Q: There was concerns a few months ago regarding PLI's cash constraints and their ability to move from development to sales of the drugs. How does 5I view their cash position now ? Are they cashed up enough to make something happen this year ?
Thank You
Clarence

Q: I would appreciate your comments concerning the press releases issued this morning by PLI and DOL. Both releases seem encouraging to me.

Thank you, Peter

Q: Hello 5i team,
I have only one entry for healthcare (GUD) and was wondering if it is a good idea to add another security seeing as this sector is beaten down? If so do you have any suggestions?
Thanks,
Andrew

Q: I would appreciate your comments about the press release issued today by PLI concerning a new financing agreement. It looks to me like a sensible and encouraging development. Thank you, Peter

Q: I am considering adding to my position in CZO, NLN AND PLI at these lower prices. Would you support this action?? And, would you please rank these three companies in terms of potential growth/ Thanks for your help

Q: Morning Team,
is it time to add to DBO, PLI and/or ALA.r ?

Q: Hello. How does the 5I team rate the quality of the management of PLI? Has PLI also given any indication of product releases for 2017 given that their drug tests favourably in all tests and has orphan drug status?
Thank You
Clarence

Q: Hi 5i,
Looking to add a specialty pharmaceutical with growth potential in a TFSA. Willing to wait for the growth and am comfortable with the risk. Morningstar rates both of these as 'undervalued' currently. Which do you prefer for future growth prospects? Thank-you.

Q: Prometic: you are probably up to speed on this one by now but do not see anything on the Q&A section. But California Capital Equity picked up 44M shares ... warrants at 0.47 cents. Dumb questions looking at the drop in price today (-7%). I am assuming this is not looked upon favourably?

Q: Regarding PLI's drop, if there is no apparent reason, does it indicate that the stock is being manipulated in some way? Does a halt like this with no apparent reason for the drop concern 5i as it is one of your "holdings"?

Q: In replying to Jim regarding PLI being halted you mentioned that the company had issued a press release indicating there were no material events to account for the drop. The last press release listed on PLI's website is dated Feb 6. Neither the website of TSX nor IIROC mention PLI's press release. Where did you see it? Is it available to the general public? If so can you tell me where?
Thanks

Q: Trading was halted. Know of any reason? Jim

Q: Hi Team, I echo the others to say thanks re: TNC, I have doubled my investment. I will replace with 2 different holdings and would like something of the same risk dynamic. In my small/cap higher risk category, I own PHO and a half position of DBO (down 35%). I also own PLI and LTE. I am up on everything except DBO. You have suggested ITC, which I don't yet own yet, is there another holding that you could suggest that would fit the description of a good quality company with growth potential, although higher risk? Should I add the other half position of DBO? Thanks as always.

Q: any ides what is pushing PLI up today?

Q: I own 1000 to 3000 shares in each of these three Companies and am considering adding to 2 of them. Which 2 would you recommend. I really appreciate your thoughts. Thanks

Q: I realize that I have a poor understanding of how to value "pre-sales" biotech companies such as TR. How is a quantitative value placed on them - I assume it is based somehow on the potential market share of the company in the specific area they are developing drugs for, as well as the size of that market and the risk of getting product to commercial trade. But this seems all very subjective. For example, TRIL has traded all over the map, the value can seem to double or be cut in half based on some combination of risk profile vs. potential. For the average retail investor, how does one go about trying to value these companies, or is is better to wait until sales start to happen and then try to value to company on sales projection? Other examples could be PLI, or one I'm still trying to forget from years past, ISA. I'm wondering if these types of companies have a place in a responsible portfolio even one is "high growth" oriented?

Q: Now that PLI has received orphan drug designation for PBI-4050, what is the liklihood the stock will rise to $4.75 as predicted? If it does reach that level, is that a take-off point to much higher levels?
Elmer

Q: I read your summary back in December on MSL. It was not flattering. As you expected the stock continues to languish. Are there other Companies in this space you would prefer and would you sell MSL (small holding) to buy it?